Trial Outcomes & Findings for Evaluation of Dryness in a Silicone Hydrogel Daily Disposable Contact Lens (NCT NCT04849780)
NCT ID: NCT04849780
Last Updated: 2022-10-10
Results Overview
Comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The change from baseline was calculated as 2-week follow-up minus baseline. The average change from baseline was reported for each arm. the change from baseline ranges from -120 to 120 where higher change from baseline comfort scores indicates a more favorable performance.
COMPLETED
NA
95 participants
Up to 2-Week Follow-up
2022-10-10
Participant Flow
A total of 95 subjects were enrolled in this study. Of those enrolled, 47 were randomized to Arm1 and dispensed at least one study lens, while 45 subjects were randomized to Arm 2 and were dispensed at least 1 study lenses. All dispensed subjects in Arm 1 completed the study while only 39 of those dispensed in Arm 2 completed the study. A total of 6 subjects were discontinued from Arm 2.
Participant milestones
| Measure |
Arm 2
Subjects randomized to this Arm were dispensed their habitual lenses A for approximately 2 weeks, then returned for follow-up evaluation. Subjects were then dispensed senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
|
Arm 1
Subjects randomized to this Arm were dispensed the senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
|
|---|---|---|
|
Period 1
STARTED
|
45
|
47
|
|
Period 1
COMPLETED
|
41
|
47
|
|
Period 1
NOT COMPLETED
|
4
|
0
|
|
Period 2
STARTED
|
41
|
0
|
|
Period 2
COMPLETED
|
39
|
0
|
|
Period 2
NOT COMPLETED
|
2
|
0
|
Reasons for withdrawal
| Measure |
Arm 2
Subjects randomized to this Arm were dispensed their habitual lenses A for approximately 2 weeks, then returned for follow-up evaluation. Subjects were then dispensed senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
|
Arm 1
Subjects randomized to this Arm were dispensed the senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
|
|---|---|---|
|
Period 1
Covid-19 Related
|
1
|
0
|
|
Period 1
Subject no longer meet eligibility criteria
|
3
|
0
|
|
Period 2
Subject no longer meet eligibility criteria
|
2
|
0
|
Baseline Characteristics
Evaluation of Dryness in a Silicone Hydrogel Daily Disposable Contact Lens
Baseline characteristics by cohort
| Measure |
Arm 1
n=47 Participants
Subjects randomized to this Arm were dispensed the senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
|
Arm 2
n=45 Participants
Subjects randomized to this Arm were dispensed their habitual lenses A for approximately 2 weeks, then returned for follow-up evaluation. Subjects were then dispensed senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
|
Total
n=92 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
34.6 years
STANDARD_DEVIATION 8.14 • n=93 Participants
|
34.0 years
STANDARD_DEVIATION 8.42 • n=4 Participants
|
34.3 years
STANDARD_DEVIATION 8.23 • n=27 Participants
|
|
Sex: Female, Male
Female
|
31 Participants
n=93 Participants
|
34 Participants
n=4 Participants
|
65 Participants
n=27 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=93 Participants
|
11 Participants
n=4 Participants
|
27 Participants
n=27 Participants
|
|
Race/Ethnicity, Customized
Asian
|
1 participants
n=93 Participants
|
0 participants
n=4 Participants
|
1 participants
n=27 Participants
|
|
Race/Ethnicity, Customized
White
|
45 participants
n=93 Participants
|
45 participants
n=4 Participants
|
90 participants
n=27 Participants
|
|
Race/Ethnicity, Customized
Other
|
1 participants
n=93 Participants
|
0 participants
n=4 Participants
|
1 participants
n=27 Participants
|
|
Region of Enrollment
United States
|
47 participants
n=93 Participants
|
45 participants
n=4 Participants
|
92 participants
n=27 Participants
|
PRIMARY outcome
Timeframe: Up to 2-Week Follow-upPopulation: Subjects that completed all required study visits without a major protocol deviation impacting a primary or secondary endpoint.
Comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The change from baseline was calculated as 2-week follow-up minus baseline. The average change from baseline was reported for each arm. the change from baseline ranges from -120 to 120 where higher change from baseline comfort scores indicates a more favorable performance.
Outcome measures
| Measure |
Arm 1
n=46 Participants
Subjects that wore the senofilcon A lens for 2-weeks and then exited the study.
|
Arm 2 (Subjects' Own Contact Lens)
n=39 Participants
Subjects that wore their habitual lenses for 2-weeks and then wore senofilcon A for 2-weeks and then exited the study.
|
|---|---|---|
|
Change From Baseline Comfort Score
|
28.99 Units on a scale
Standard Deviation 26.766
|
-0.29 Units on a scale
Standard Deviation 10.245
|
SECONDARY outcome
Timeframe: Up to 2-Week Follow-upPopulation: Subjects that completed all required study visits without a major protocol deviation impacting a primary or secondary endpoint.
The CLDEQ-8 is a validated outcome measure for soft contact lenses wearers. It has been highly correlated with habitual baseline status and change in overall opinion when subjects are refit with contact lenses. A CLDEQ-8 total score of ≥12 is proposed to identify contact lens wearers who could benefit from clinical management of their contact lens related symptoms. A three-point change in CLDEQ-8 total scores has also been shown to be clinically important. This study will include the symptomatic subjects who will have a CLDEQ total score of ≥15. CLDEQ-8 scores range from 0 to 30 where, higher CLDEQ-8 score indicates more dry eye symptoms with respect to contact lens wear. The change is calculated as 2-week minus Baseline. The change from baseline CLDEQ-8 score ranges from -30 to 30 where lower change from baseline CLDEQ-8 scores indicate better performance. The average change in CLDEQ-8 for each arm was reported.
Outcome measures
| Measure |
Arm 1
n=46 Participants
Subjects that wore the senofilcon A lens for 2-weeks and then exited the study.
|
Arm 2 (Subjects' Own Contact Lens)
n=39 Participants
Subjects that wore their habitual lenses for 2-weeks and then wore senofilcon A for 2-weeks and then exited the study.
|
|---|---|---|
|
Change From Baseline CLDEQ-8 Score
|
-10.83 Unit on a scale
Standard Deviation 6.631
|
-1.23 Unit on a scale
Standard Deviation 3.638
|
SECONDARY outcome
Timeframe: 2-Week Follow-upPopulation: Subjects randomized to Arm 2 and completed all required study visits without a major protocol deviation impacting a primary or secondary endpoint.
Comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The average comfort score was reported for each group within Arm 2 only.
Outcome measures
| Measure |
Arm 1
n=39 Participants
Subjects that wore the senofilcon A lens for 2-weeks and then exited the study.
|
Arm 2 (Subjects' Own Contact Lens)
n=39 Participants
Subjects that wore their habitual lenses for 2-weeks and then wore senofilcon A for 2-weeks and then exited the study.
|
|---|---|---|
|
Comfort Score
|
55.88 Unit on a scale
Standard Deviation 25.721
|
29.69 Unit on a scale
Standard Deviation 13.849
|
SECONDARY outcome
Timeframe: 2-Week Follow-upPopulation: Subjects randomized to Arm 2 and completed all required study visits without a major protocol deviation impacting a primary or secondary endpoint.
The CLDEQ-8 is a validated outcome measure for soft contact lenses wearers. It has been highly correlated with habitual baseline status and change in overall opinion when subjects are refit with contact lenses. A CLDEQ-8 total score of ≥12 is proposed to identify contact lens wearers who could benefit from clinical management of their contact lens related symptoms. A three-point change in CLDEQ-8 total scores has also been shown to be clinically important. This study will include the symptomatic subjects who will have a CLDEQ total score of ≥15. CLDEQ-8 scores range from 0 to 30 where, higher CLDEQ-8 score indicates more dry eye symptoms with respect to contact lens wear. The average CLDEQ-8 for each arm was reported.
Outcome measures
| Measure |
Arm 1
n=39 Participants
Subjects that wore the senofilcon A lens for 2-weeks and then exited the study.
|
Arm 2 (Subjects' Own Contact Lens)
n=39 Participants
Subjects that wore their habitual lenses for 2-weeks and then wore senofilcon A for 2-weeks and then exited the study.
|
|---|---|---|
|
CLDEQ-8 Score
|
12.46 Unit on a scale
Standard Deviation 6.078
|
21.18 Unit on a scale
Standard Deviation 3.698
|
Adverse Events
Senofilcon A
Nelfilcon A
Delfilcon A
Somofilcon A
Stenofilcon A
Etafilcon A
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Senofilcon A
n=88 participants at risk
Subjects that wore the senofilcon A lens in either Arm of the study.
|
Nelfilcon A
n=11 participants at risk
Subjects that wore the nelfilcon A lens during the first period in Arm 2
|
Delfilcon A
n=10 participants at risk
Subjects that wore the delfilcon A lens during the first period in Arm 2
|
Somofilcon A
n=5 participants at risk
Subjects that wore the somofilcon A lens during the first period in Arm 2
|
Stenofilcon A
n=2 participants at risk
Subjects that wore the stenofilcon A lens during the first period in Arm 2
|
Etafilcon A
n=17 participants at risk
Subjects that wore the etafilcon A lens during the first period in Arm 2
|
|---|---|---|---|---|---|---|
|
Infections and infestations
Covid - 19
|
0.00%
0/88 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
|
0.00%
0/11 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
|
0.00%
0/10 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
|
0.00%
0/5 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
|
50.0%
1/2 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
|
0.00%
0/17 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
|
Additional Information
John R. Buch, OD, MS, FAAO
Johnson & Johnson Vision Care, Inc.
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60